Revolution Medicines, Inc. (RVMD) research

Revolution Medicines, Inc.
ShareXLinkedInReddit
Sector
Biotechnology
Last price
$206.64
As of

Revolution Medicines, Inc. (RVMD): 5 institutional managers tracked by Kresmion reported non-option positions in their 2026Q2 Form 13F filings, and the most recent SEC filing on record for the company is a Form 8-K filed 2026-09-01.

As of . Source: SEC EDGAR filings for RVMD. Method and limitations.

SHARE THIS CARD

Share the RVMD intelligence card

A branded snapshot of RVMD: the smart money composite, cross family confluence, and the top current signal, with a link back to this page. Post it, download it, or embed it anywhere.

Kresmion RVMD intelligence card preview
Post to X
COMPANY DOSSIER

See the full RVMD dossier

Price with insider and filing markers, who is positioning, fundamentals and peers for RVMD on one page. Preview it with sample data, then open it live with a free account.

Preview the RVMD dossier

Active signals for RVMD

FREE, NO ACCOUNT

Every signal on RVMD, as it fires

You are seeing 5 of 26 signals recorded on RVMD since 2026-06-05.

The five above landed across 2 days. The other 21 were recorded on 4 other days. 16 of the 26 are institutional flow rows, which arrive in batches on filing days.

Get it by email

No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.

Join on Telegram
Join on Telegram

One tap. Live alerts, no email needed.

Largest reported share positions in RVMD (2026Q2)

Manager / securityMarket value% portfolioQoQ
TWO SIGMA INVESTMENTS, LPCUSIP 76155X100 · 2026Q2$138.2M0.10%,
CITADEL ADVISORS LLCCUSIP 76155X100 · 2026Q2$110.5M0.01%,
MILLENNIUM MANAGEMENT LLCCUSIP 76155X100 · 2026Q2$40.5M0.01%,
Point72 Asset Management, L.P.CUSIP 76155X100 · 2026Q2$11.3M0.01%,
MILLENNIUM MANAGEMENT LLCCUSIP 76155XAA8 · 2026Q2$6.4M0.00%,
D. E. Shaw & Co., Inc.CUSIP 76155X100 · 2026Q2$2.3M0.00%,

Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.

Recent SEC filings, RVMD

RVMD against its peers

RVMD's return on equity of -69.3% ranks in the 12th percentile of 20 Biotechnology sub-industry peers, fiscal periods ending between 2025-12-31 and 2026-03-31.

MetricRVMDPeer medianPercentilen
Revenue FY0.0 USD2.4B USD319
Operating marginn/a17.6%n/a20
Net marginn/a13.1%n/a21
Return on equity-69.3%11.2%1220
P / En/a30.7xn/a11

Peers (22): ONC, ARGX, NTRA, BIIB, ALNY, REGN, MRNA, ROIV, RPRX, BNTX, INSM, INCY, GMAB, UTHR, VRTX, ASND, EXEL, NBIX, SMMT, BBIO, HALO, MDGL. Left out: CSLLY (no annual filing), IVBXF (no annual filing), SBMFF (no annual filing). Fiscal periods ending between 2025-12-31 and 2026-03-31. Every figure is one full fiscal year read from one annual filing (RVMD: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.

Related tickers

See more RVMD signals as they fire

Kresmion publishes filings, 13F flows, on-chain whale activity, and cross-asset signals in real time. Open a live board scoped to RVMDand get the insider, 13F, options, and confluence read in one view.

Preview the RVMD dossier